Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.

Case reports in hematology

Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ.
PMID: 26180646
Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09.

Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune globulin,...

Cite
Anwer F, Yun S, Nair A, et al. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451doi: 10.1155/2015/583451.
Anwer, F., Yun, S., Nair, A., Ahmad, Y., Krishnadashan, R., & Deeg, H. J. (2015). Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case reports in hematology, 2015583451. https://doi.org/10.1155/2015/583451
Anwer, Faiz, et al. "Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag." Case reports in hematology vol. 2015 (2015): 583451. doi: https://doi.org/10.1155/2015/583451
Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09. PMID: 26180646; PMCID: PMC4477130.
Copy Download .nbib Format: NLM
High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura.

Journal of clinical and diagnostic research : JCDR

Swain TR, Jena RK, Swain KP.
PMID: 28208873
J Clin Diagn Res. 2016 Dec;10(12):FC12-FC15. doi: 10.7860/JCDR/2016/20347.8976. Epub 2016 Dec 01.

INTRODUCTION: Immune Thrombocytopenia (ITP) is characterised by an autoimmune antibody-mediated destruction of platelets and impaired platelet production. Few controlled trials exist to guide management of patients with ITP in Indian scenario for which patients require an individualized approach. Anti-D...

Cite
Swain TR, Jena RK, Swain KP. High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura. J Clin Diagn Res. 2016;10(12):FC12-FC15doi: 10.7860/JCDR/2016/20347.8976.
Swain, T. R., Jena, R. K., & Swain, K. P. (2016). High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura. Journal of clinical and diagnostic research : JCDR, 10(12), FC12-FC15. https://doi.org/10.7860/JCDR/2016/20347.8976
Swain, Trupti Rekha, et al. "High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura." Journal of clinical and diagnostic research : JCDR vol. 10,12 (2016): FC12-FC15. doi: https://doi.org/10.7860/JCDR/2016/20347.8976
Swain TR, Jena RK, Swain KP. High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura. J Clin Diagn Res. 2016 Dec;10(12):FC12-FC15. doi: 10.7860/JCDR/2016/20347.8976. Epub 2016 Dec 01. PMID: 28208873; PMCID: PMC5296446.
Copy Download .nbib Format: NLM
Misleading hepatitis B serology following Rho (D) immune globulin (human) injection and influenza vaccine.

Clinics and practice

Chen X.
PMID: 29657700
Clin Pract. 2018 Mar 21;8(2):1037. doi: 10.4081/cp.2018.1037. eCollection 2018 Mar 28.

Having a hepatitis B surface antibody (HBsAb) titre of more than 10 mIU/mL after hepatitis B vaccination is generally considered to confer immunity to hepatitis B. This case report discusses an unusual case of a false positive hepatitis B...

Cite
Chen X. Misleading hepatitis B serology following Rho (D) immune globulin (human) injection and influenza vaccine. Clin Pract. 2018;8(2):1037doi: 10.4081/cp.2018.1037.
Chen, X. (2018). Misleading hepatitis B serology following Rho (D) immune globulin (human) injection and influenza vaccine. Clinics and practice, 8(2), 1037. https://doi.org/10.4081/cp.2018.1037
Chen, Xuanxuan. "Misleading hepatitis B serology following Rho (D) immune globulin (human) injection and influenza vaccine." Clinics and practice vol. 8,2 (2018): 1037. doi: https://doi.org/10.4081/cp.2018.1037
Chen X. Misleading hepatitis B serology following Rho (D) immune globulin (human) injection and influenza vaccine. Clin Pract. 2018 Mar 21;8(2):1037. doi: 10.4081/cp.2018.1037. eCollection 2018 Mar 28. PMID: 29657700; PMCID: PMC5890088.
Copy Download .nbib Format: NLM
Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial.

Obstetrics & gynecology science

Mayekar RV, Paradkar GV, Bhosale AA, Sachan R, Beeram S, Anand AR, Mundle SR, Trivedi Y, Md R, Patole KP, Sambarey PW, Daftary GV, John J, Divekar GH.
PMID: 32489976
Obstet Gynecol Sci. 2020 May;63(3):315-322. doi: 10.5468/ogs.2020.63.3.315. Epub 2020 Apr 21.

OBJECTIVE: To compare the efficacy and safety of recombinant anti-D (R-anti-D) with conventional polyclonal anti-D (Poly anti-D) in preventing maternal-fetal rhesus D (RhD) alloimmunization and to investigate the immunogenicity of R-anti-D.METHODS: This was a randomized, open-label, multi-center clinical trial...

Cite
Mayekar RV, Paradkar GV, Bhosale AA, et al. Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial. Obstet Gynecol Sci. 2020;63(3):315-322doi: 10.5468/ogs.2020.63.3.315.
Mayekar, R. V., Paradkar, G. V., Bhosale, A. A., Sachan, R., Beeram, S., Anand, A. R., Mundle, S. R., Trivedi, Y., Md, R., Patole, K. P., Sambarey, P. W., Daftary, G. V., John, J., & Divekar, G. H. (2020). Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial. Obstetrics & gynecology science, 63(3), 315-322. https://doi.org/10.5468/ogs.2020.63.3.315
Mayekar, Rahul Vishwanath, et al. "Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial." Obstetrics & gynecology science vol. 63,3 (2020): 315-322. doi: https://doi.org/10.5468/ogs.2020.63.3.315
Mayekar RV, Paradkar GV, Bhosale AA, Sachan R, Beeram S, Anand AR, Mundle SR, Trivedi Y, Md R, Patole KP, Sambarey PW, Daftary GV, John J, Divekar GH. Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial. Obstet Gynecol Sci. 2020 May;63(3):315-322. doi: 10.5468/ogs.2020.63.3.315. Epub 2020 Apr 21. PMID: 32489976; PMCID: PMC7231934.
Copy Download .nbib Format: NLM
Rho(D) immune globulin to prevent RH hemolytic disease.

American family physician

White CA, Liesch MR, Richerson HB, Goplerud CP.
PMID: 5541866
Am Fam Physician. 1971 Feb;3(2):85-9.

No abstract available.

Cite
White CA, Liesch MR, Richerson HB, et al. Rho(D) immune globulin to prevent RH hemolytic disease. Am Fam Physician. 1971;3(2):85-9
White, C. A., Liesch, M. R., Richerson, H. B., & Goplerud, C. P. (1971). Rho(D) immune globulin to prevent RH hemolytic disease. American family physician, 3(2), 85-9.
White, C A, et al. "Rho(D) immune globulin to prevent RH hemolytic disease." American family physician vol. 3,2 (1971): 85-9.
White CA, Liesch MR, Richerson HB, Goplerud CP. Rho(D) immune globulin to prevent RH hemolytic disease. Am Fam Physician. 1971 Feb;3(2):85-9. PMID: 5541866.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries